May 2024 Patent Highlights: STING Antagonists, WIZ Degraders, Macrocyclic Amine-Based OX2R Modulators, and More

This summary of September's major clinical updates features FDA approvals, drug withdrawals, anticipated regulatory decisions, notable trial results, new NDA submissions, clinical trial setbacks, and the initiation of new clinical trials.

Staying on top of the latest IP disclosures in drug discovery is no small feat, so we’ve made it easier for you! Our team sifted through thousands of recently published patents to compile a curated list of about 200 significant patent documents in the drug discovery space from September 2024. Each entry is accompanied by detailed annotations to help you quickly grasp the essentials.

The 2024 SABCS brought together over 10,000 attendees from more than 100 countries, including leading academics, researchers, patient advocates, and healthcare professionals, to showcase state-of-the-art advances in breast cancer research. In our highlights, we will cover exciting clinical trial updates from this year’s symposium, including targeted molecules addressing key pathways such as CDK4, CDK2, and PI3Kα, along with advancements in next-generation oral SERDs (selective estrogen receptor degraders).

Here’s a quick recap of the top business news from October, including major deals, acquisitions, funding rounds, and strategic partnerships. If you missed any updates, here’s your chance to catch up on the most significant developments in the industry.

In this article, we present a curated selection of over 60 molecules from September that caught our attention, along with highlights of our top picks and insights into why they stand out.